Evidence map›Paper›PMID 37927472›Full record

ArticleFrontiers in oncology2023

Comprehensive NGS profiling to enable detection of

Sergi Clavé, Jennifer B Jackson, Marta Salido, Jacob Kames, Kelly M R Gerding, Ellen L Verner, Eric F Kong, Elizabeth Weingartner, Joan Gibert, Max Hardy-Werbin and 11 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 2 countries.

Sergi ClavéPathology Department, Hospital del Mar, Barcelona, Spain.
Jennifer B JacksonPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Marta SalidoPathology Department, Hospital del Mar, Barcelona, Spain.
Jacob KamesPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Kelly M R GerdingPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Ellen L VernerPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Eric F KongPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Elizabeth WeingartnerPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Joan GibertCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Max Hardy-WerbinCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Pedro RochaCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Xènia RieraPathology Department, Hospital del Mar, Barcelona, Spain.
Erica TorresPathology Department, Hospital del Mar, Barcelona, Spain.
James HernandezPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Gustavo CerqueiraPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Donna NicholPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
John SimmonsPersonal Genome Diagnostics (PGDx/Labcorp), Baltimore, MD, United States.
Álvaro TausCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Lara PijuanPathology Department, Hospital del Mar, Barcelona, Spain.
Beatriz BellosilloPathology Department, Hospital del Mar, Barcelona, Spain.
Edurne ArriolaCancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Hospital Del Mar · ESLabCorp (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Next-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead to the better characterization of a tumor's molecular landscape. However, further evaluation of technical aspects related to the detection of gene rearrangements and copy number alterations is warranted. Methods: There were 12 Results: The detection of Discussion: Overall, this study validates NGS as an accurate approach for detecting structural variants while also highlighting the need for further optimization to enable harmonization across methodologies for amplifications.

Indexed as

ALK rearrangementbiomarkersfluorescence in situ hybridization (FISH)MET amplificationmolecular testingnext generation sequencing (NGS)non-small cell lung cancer (NSCLC)

Identifiers

PMID37927472
PMCPMC10623306
OpenAlexW4387821764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.